Journal article
The Effects of Noncompliance to Prolia (Denosumab) on the Changes in Bone Mineral Density: A Retrospective Review
Abstract
Although denosumab (Prolia) has been shown to be a safe and efficacious therapy for osteoporotic patients in numerous clinical trials, few studies have determined its effectiveness in real world clinical practice. A retrospective review of patients prescribed Prolia assessing the impact that noncompliance from the regular dosing regimen of six months for denosumab has on bone mineral density (BMD) was performed. 924 patient records were …
Authors
Wong-Pack M; Kalani A; Hordyk J; Ioannidis G; Bensen R; Bensen WG; Papaioannou A; Adachi JD; Lau AN
Journal
Journal of Osteoporosis, Vol. 2016, No. 1,
Publisher
Hindawi
Publication Date
2016
DOI
10.1155/2016/7903128
ISSN
2090-8059